Immuneering News

Immuneering | DEFA14A: Others

Apr 24 04:21

Immuneering | DEF 14A: Definitive information statements

Apr 24 04:17

Immuneering | 8-K: Current report

Mar 14 19:08

Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -

Mar 1 21:06

Immuneering | 8-K: Current report

Feb 3 05:17

Immuneering | 8-K: Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in

Nov 10, 2023 05:05

Immuneering | 8-K: Current report

Aug 4, 2023 04:04

Immuneering | 8-K: Current report

Jun 16, 2023 04:15

Immuneering | 8-K: Current report

Jun 15, 2023 04:08

Immuneering | 8-K: Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

May 5, 2023 04:03

Immuneering | DEFA14A: Others

May 1, 2023 19:29

Immuneering | DEF 14A: Definitive proxy statements

May 1, 2023 19:28

Immuneering | 8-K: Current report

Apr 20, 2023 04:07

Immuneering | 8-K: Current report

Apr 18, 2023 21:04

Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 7, 2023 05:05

Immuneering | 8-K: Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 10, 2022 22:00

Immuneering: Current report (Amendment)

8-K/A | Immuneering Corp (0001790340) (Filer)

Sep 20, 2022 04:30

Immuneering | S-3: Registration statement for specified transactions by certain issuers

Aug 11, 2022 04:39

Immuneering | 8-K: Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 11, 2022 04:05

Immuneering | 8-K: Current report

Jul 25, 2022 19:00